Ribociclib,
does it really help with Prolonged overall survival with first-line ribociclib plus letrozole in HR-positive, HER2-negative advanced breast cancer?
research showsGrade A evidence shows that adding ribociclib to letrozole prolongs overall survival as first-line therapy for postmenopausal patients with HR-positive, HER2-negative advanced breast cancer. In the final analysis of the 668-participant, phase 3 MONALEESA-2 trial, median overall survival was 63.9 versus 51.4 months, with a death hazard ratio of 0.76 (95% CI 0.63 to 0.93; P=0.008); an earlier analysis also improved progression-free survival to 25.3 versus 16.0 months, hazard ratio 0.568. A protocol-specified final survival analysis with hierarchical testing established a direct hard endpoint, supporting A with 91 points. Neutropenia, hepatotoxicity, and QTc prolongation require active monitoring separately from efficacy.
ads claimA 12.5-month difference between median survival estimates does not mean that every patient lives exactly 12.5 months longer, and a 24% mortality-hazard reduction is not a 24-percentage-point absolute survival increase. Evidence concerns first-line ribociclib combined with letrozole, not ribociclib alone.
Useful facts when choosing a product
- MONALEESA-2 used ribociclib 600 mg once daily for 21 days of each 28-day cycle with letrozole 2.5 mg daily.
- The survival evidence applies most directly to first-line systemic treatment of postmenopausal HR-positive, HER2-negative advanced breast cancer.
- Complete blood counts are required because of neutropenia and infection risk, and liver function requires regular monitoring because liver enzymes can rise.
- QTc prolongation requires review of electrocardiograms, electrolytes, and interacting drugs, with interruptions or dose reductions guided by the product label and oncology team.
What the research actually shows
Hortobagyi and colleagues randomized 668 MONALEESA-2 participants to ribociclib 600 mg for 21 days followed by 7 days off plus daily letrozole 2.5 mg, or placebo plus letrozole. The initial primary analysis showed a progression-free-survival hazard ratio of 0.56, and the updated analysis confirmed median progression-free survival of 25.3 versus 16.0 months, hazard ratio 0.568. At the final analysis after 6.6 years of median follow-up, 181 of 334 patients had died with ribociclib versus 219 of 334 with placebo; median overall survival was 63.9 versus 51.4 months, hazard ratio 0.76. Survival efficacy is strong, while neutropenia, leukopenia, liver-enzyme elevation, and QTc prolongation require separate monitoring.
Why this is classified as A (91)
The 668-participant, double-blind, phase 3 MONALEESA-2 trial significantly improved protocol-specified, hierarchically tested final overall survival to 63.9 versus 51.4 months, hazard ratio 0.76, with a large concordant progression-free-survival benefit. Deductions for one manufacturer program and a key secondary endpoint are outweighed by the direct survival result and corpus alignment with tamoxifen A96, supporting A with 91 points.
Counterpoint. Menopausal status, disease burden, cardiac and hepatic function, and alternative endocrine or targeted treatments can change absolute benefit and suitability.
Rejudgment record. New verdict — Applied grade A for protocol-specified, hierarchically tested final overall survival of 63.9 versus 51.4 months, hazard ratio 0.76, in the 668-participant double-blind phase 3 MONALEESA-2 trial, supported by primary progression-free survival of 25.3 versus 16.0 months, hazard ratio 0.568, the prescription-drug hard-endpoint exception, and breast-cancer survival corpus alignment with tamoxifen A96
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prolonged overall survival with first-line letrozole | A | Final median overall survival was 63.9 versus 51.4 months, with a direct hard-endpoint death hazard ratio of 0.76. |
| Prolonged progression-free survival with first-line letrozole | A | The prespecified primary endpoint was large and consistent at 25.3 versus 16.0 months, hazard ratio 0.568, and the overall-survival benefit mitigates surrogacy concerns. |
| Increased objective tumor response | B | Response increased among patients with measurable disease, but it remains an imaging-based secondary surrogate. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Protocol-specified final overall-survival analysis of a randomized double-blind placebo-controlled phase 3 trial | 668 | Novartis | Hierarchically tested key secondary overall survival | Median overall survival was 63.9 versus 51.4 months, with a death hazard ratio of 0.76 (95% CI 0.63 to 0.93; P=0.008). | Pivotal direct survival endpoint |
| Study 2 | Updated progression-free-survival analysis of the same randomized double-blind phase 3 trial | 4 | Novartis | Primary progression-free survival; secondary response and safety | Median progression-free survival was 25.3 versus 16.0 months, hazard ratio 0.568 (95% CI 0.457 to 0.704). | Support from the primary endpoint; not an independent replication |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-22).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-22 · Corrections: none
Cite this verdict
[Chamgap] Ribociclib x prolonged first-line overall survival in HR-positive, HER2-negative advanced breast cancer — Evidence Grade A·91. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/ribociclib-letrozole-first-line-hr-positive-her2-negative-advanced-breast-cancer-overall-survival/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.